Multiple Immune-Related Adverse Events and Anti-Tumor Efficacy: Real-World Data on Various Solid Tumors

PURPOSE: Immune checkpoint inhibitors (ICIs) have been approved for various types of cancer; however, they cause a broad spectrum of immune-related adverse events (irAEs). The association between the development of irAEs and the clinical benefit remains uncertain. We aimed to evaluate the associatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Shimozaki, Keitaro, Sukawa, Yasutaka, Beppu, Noriko, Kurihara, Isao, Suzuki, Shigeaki, Mizuno, Ryuichi, Funakoshi, Takeru, Ikemura, Shinnosuke, Tsugaru, Kai, Togasaki, Kazuhiro, Kawasaki, Kenta, Hirata, Kenro, Hayashi, Hideyuki, Hamamoto, Yasuo, Takaishi, Hiromasa, Kanai, Takanori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7305832/
https://www.ncbi.nlm.nih.gov/pubmed/32606951
http://dx.doi.org/10.2147/CMAR.S247554

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7305832/
https://www.ncbi.nlm.nih.gov/pubmed/32606951
http://dx.doi.org/10.2147/CMAR.S247554

Ejemplares similares